Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

HKG:6990 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	2,086	2,058	1,933	1,540	803.93	32.32
Revenue Growth	1.35%	6.46%	25.48%	91.62%	2387.26%	-
Gross Profit Gross Profit Growth	1,556	1,479	1,274	759.19	526.8	9.25
Operating Income Operating Income Growth	-4.15	-419.57	-279.22	-453.7	-393.95	-795.24
Net Income Net Income Growth	151.21	-381.97	-266.77	-522.21	-548.1	-822.55
Earnings Per Share EPS Growth	0.65	-1.66	-1.20	-2.84	-5.74	-8.90
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
The PRC The PRC Growth	912.59	571.2	92.65	7.54	56.49	20.39
The United States of America The United States of America Growth	1,121	1,315	1,840	1,528	730.04	-
Switzerland Switzerland Growth	48.76	168.69	-	-	-	-
Other Countries Other Countries Growth	-	3.31	-	4.73	17.41	11.94
Total Total Growth	2,086	2,058	1,933	1,540	803.93	32.32

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	4,778	4,472	3,069	2,488	92.96	81.79
Total Debt Total Debt Growth	81.35	88.44	126.75	59.92	3,014	2,391
Net Cash (Debt) Net Cash Growth	4,696	4,383	2,942	2,428	-2,921	-2,309
Net Cash Growth	7.14%	48.99%	21.15%	-	-	-
Net Cash Per Share Net Cash Per Share Growth	20.13	19.01	13.27	13.22	-30.58	-24.98

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	531.69	-180.3	-429.77	59.56	-270.85	-485.94
Capital Expenditures CapEx Growth	-110.89	-125.69	-77.46	-80.98	-33.66	-94.08
Free Cash Flow Free Cash Flow Growth	420.8	-305.99	-507.23	-21.42	-304.51	-580.03
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	74.59%	71.86%	65.89%	49.28%	65.53%	28.62%
Operating Margin	-0.20%	-20.39%	-14.45%	-29.45%	-49.00%	-2460.37%
Pretax Margin	3.25%	-17.29%	-7.37%	-30.36%	-70.57%	-2752.91%
Profit Margin	7.25%	-18.56%	-13.80%	-33.90%	-68.18%	-2544.86%
FCF Margin	20.17%	-14.87%	-26.24%	-1.39%	-37.88%	-1794.52%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PS Ratio	48.34	39.94	18.04	13.29	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 17, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 30, 2026

Data Sources Report a data error